ClinicalTrials.Veeva

Menu

Controlling and Lowering Blood Pressure With The MOBIUS HD™ (CALM-FIM_EUR)

V

Vascular Dynamics

Status

Completed

Conditions

Hypertension

Treatments

Device: MobiusHD

Study type

Interventional

Funder types

Industry

Identifiers

NCT01911897
CRD0120, CRD0233

Details and patient eligibility

About

To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.

Full description

This is an open-label, multicenter, first-in-man clinical trial to be conducted in Europe. Eligible subjects with stage 2 resistant systemic arterial hypertension currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the MobiusHD system.

Potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo placement of the MobiusHD under angiographic visualization, and will then be followed for 36 months.

Enrollment

30 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Office cuff SBP ≥ 160 mmHg measured per protocol instructions following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications.

Exclusion criteria

  • Known or clinically suspected baroreflex failure or autonomic neuropathy

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

MobiusHD
Experimental group
Description:
MobiusHD
Treatment:
Device: MobiusHD

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems